Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eilean Therapeutics Doses First Patient with ZE46-0134, A Selective FLT3WT-Sparing, Pan FLT3Mut Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eilean Therapeutics Initiates First in Human Trial with Eiletoclax, a Selective Bcl2 Inhibitor with Limited Immune Suppression and Improved Safety Compared to Venetoclax and Venetoclax-Like Molecules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eilean Therapeutics Completes Single Dose Studies AND Initiates Multiple Dosing of Healthy Volunteers WITH Lomonitinib, a Selective Pan-FLT3\/IRAK4 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Expert Systems","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Expert Systems Expands Partnership with Eilean Therapeutics and Joins its Best-in-Class PTPN2 Inhibitor Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Expert Systems","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Expert Systems Celebrates Accelerated Start of Human Dosing for Eiletoclax, a Selective BCL2 Inhibitor, Achieved in Just 3 Years","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eilean Therapeutics Approved to Initiate First Patient Trial with Balamenib (ze63-0302), a Selective Best-In-Class Menin Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eilean Therapeutics Receives Clearance to Initiate R\/R AML Trial with Lomonitinib, a Selective Pan-FLT3\/IRAK4 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"}]

    Find Clinical Drug Pipeline Developments & Deals by Eilean Therapeutics

    Menu

    Eilean Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Eilean Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eilean Therapeutics Receives Clearance to Initiate R/R AML Trial with Lomonitinib, a Selective Pan-FLT3/IRAK4 Inhibitor

              Details:

              ZE46-0134 (lomonitinib) is a highly potent and selective inhibitor of FLT3 ITD, TKD and other clinically relevant FLT3 mutations, as well as IRAK4. It is being investigated for the treatment of relapsed/refractory acute myeloid leukemia.

              Lead Product(s): Lomonitinib

              Therapeutic Area: Oncology Product Name: ZE46-0134

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 04, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eilean Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Expert Systems Expands Partnership with Eilean Therapeutics and Joins its Best-in-Class PTPN2 Inhibitor Program

              Details:

              The partnership aims to support the clinical advancement of Eilean's lead PTPN2 inhibitor, which is being evaluated in the preclinical trial studies for the treatment of patients related to neoplasms.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Undisclosed

              Recipient: Expert Systems

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership March 12, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eilean Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eilean Therapeutics Approved to Initiate First Patient Trial with Balamenib (ze63-0302), a Selective Best-In-Class Menin Inhibitor

              Details:

              ZE63-0302 (balamenib) is a selective best-in-class oral small molecule inhibitor of the menin-KMT2A interaction. It is being evaluated for the treatment of hematological malignancies.

              Lead Product(s): Balamenib

              Therapeutic Area: Oncology Product Name: ZE63-0302

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 11, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eilean Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Expert Systems Celebrates Accelerated Start of Human Dosing for Eiletoclax, a Selective BCL2 Inhibitor, Achieved in Just 3 Years

              Details:

              ZE50-0134 (eiletoclax) is a selective BCL2 inhibitor, which is being evaluated for the treatment of chronic lymphocytic leukemia & acute myeloid leukemia.

              Lead Product(s): Eiletoclax

              Therapeutic Area: Oncology Product Name: ZE50-0134

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Expert Systems

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 21, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eilean Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eilean Therapeutics Initiates First in Human Trial with Eiletoclax, a Selective Bcl2 Inhibitor with Limited Immune Suppression and Improved Safety Compared to Venetoclax an...

              Details:

              ZE50-0134 (eiletoclax) is a highly potent and selective BCL2 inhibitor. It is being evaluated in phase 1 tirals for the treatment of acute myeloid leukemia & chronic lymphocytic leukemia.

              Lead Product(s): Eiletoclax

              Therapeutic Area: Oncology Product Name: ZE50-0134

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 29, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eilean Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eilean Therapeutics Completes Single Dose Studies AND Initiates Multiple Dosing of Healthy Volunteers WITH Lomonitinib, a Selective Pan-FLT3/IRAK4 Inhibitor

              Details:

              ZE46-0134 (lomonitinib) is a highly potent and selective pan-FLT3/ IRAK4 inhibitor that targets clinically relevant FLT3 mutations which is being evaluated in phase 1 clinical trials for FLT3 mutated Acute Myeloid Leukemia.

              Lead Product(s): Lomonitinib

              Therapeutic Area: Oncology Product Name: ZE46-0134

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 29, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eilean Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eilean Therapeutics Doses First Patient with ZE46-0134, A Selective FLT3WT-Sparing, Pan FLT3Mut Inhibitor

              Details:

              ZE46-0134, a highly potent and selective pan-FLT3 inhibitor that targets clinically relevant FLT3 mutations including the FLT3 gatekeeper mutation, while sparing the wild type form of the protein.

              Lead Product(s): ZE46-0134

              Therapeutic Area: Oncology Product Name: ZE46-0134

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 21, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY